CLOMID by Sanofi is clinical pharmacology action clomiphene citrate is a drug of considerable pharmacologic potency. Approved for ovulatory dysfunction in women desiring pregnancy. First approved in 1967.
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
CLOMID (clomiphene citrate) is an oral small-molecule selective estrogen receptor modulator approved in 1967 for treating anovulatory infertility in women. It works by competing with estrogen for receptor-binding sites in the hypothalamus and pituitary, triggering a cascade of gonadotropin release that initiates ovulation. The drug has mixed estrogenic and antiestrogenic properties that collectively stimulate follicular development and the preovulatory LH surge.
As LOE approaches, the brand team is likely contracting; roles focus on defending market share against generics and managing declining volumes rather than expansion.
CLINICAL PHARMACOLOGY Action Clomiphene citrate is a drug of considerable pharmacologic potency. With careful selection and proper management of the patient, clomiphene citrate has been demonstrated to be a useful therapy for the anovulatory patient desiring pregnancy. Clomiphene citrate is capable…
Worked on CLOMID at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Effect of Luteal Progesterone Support on Pregnancy Rates With Combined Clomid/ Gonadotropin & IUI
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on CLOMID offers limited career growth potential given its LOE-approaching status and minimal linked job openings (0 current postings). Roles available are primarily defensive—managing payer relationships, generic competition, and market share retention rather than driving new launches or innovation.